



Information for people
living with Fabry disease
- and their families

Plain English Campaign's Crystal Mark for clarity does not apply to the design of this guide.


Crystal Mark 23941 Clarity approved by Plain English Campaign

How is Fabry disease passed on?

- Males have an X chromosome (inherited from their mother) and a Y chromosome (inherited from their father).
- Females have two X chromosomes (one inherited from their mother and one from their father).
- Fabry disease is an X-linked disorder, meaning that it is passed on in a mutation in an X chromosome. It can be passed down by either parent if they have a mutated X chromosome.


In the following diagrams, mutated X chromosomes are shown in red. Any child who inherits a mutated X chromosome will develop Fabry disease.

How fathers pass on Fabry disease



As shown in the diagram above, if a father has the mutated X chromosome, any daughter will develop Fabry disease but sons will not.

How mothers pass on Fabry disease



As shown in the diagram above, if a mother has the mutated X chromosome, there is a 50% chance of any child (male or female) developing Fabry disease.



What do certain words mean?

A glossary of important terms when discussing Fabry disease

Cell	Chromosome	DNA (deoxyribonucleic acid)	Enzyme	Lysosomal disorder (LD)	Mutation
building block of	contains DNA and a person's genetic code.	information from one generation to the next and contains	reaction that takes place in the body.	of lysosomes	A permanent error in the DNA code.

Facts about Fabry

(For more information, talk to your healthcare provider.)



Fabry is a rare, progressive, genetic disease. It is thought to affect 1 in 117,000 people, but it may be more common than this.



Usually, α-Gal A breaks down substances called globotriaosylceramide (GL-3) and globotriaosylsphingosine (lyso-Gb3) that are in cells.



It's a type of disease called a lysosomal disorder.



In people with Fabry disease, a-Gal A does not break down GL-3. So GL-3 builds up, particularly in cells lining blood vessels.



People with lysosomal disorders have problems making specific enzymes.



This build-up damages tissues and organs, leading to the symptoms of Fabry disease.



In Fabry disease, the affected enzyme is ' α -galactosidase A', referred to as α -Gal A.

What causes Fabry disease?



Everyone has DNA, which is inherited from their parents.







Sometimes, there are mutations in the DNA code that makes up a particular gene.

Think of DNA code like spelling. One wrong letter can completely change the meaning of a word!





Some people with the mutation that causes Fabry disease make very little or no q-Gal A.




Some people with the mutation that causes Fabry disease may make α -Gal A that doesn't function correctly.



How Fabry disease could affect you

Everyone experiences Fabry disease differently, but the following are common.



Bottom line:


diagnosis of Fabry, after years

of not knowing, and shock

Talk to others with Fabry disease and share your experiences. It may help!

lower abdomen

If a doctor suspects Fabry disease, here's what might happen




- · Your doctor may suggest genetic counselling.
- Your doctor begins to create a **personalised approach** to your monitoring and treatment.
- · Your family history is taken.
- Your doctor may suggest genetic testing for other family members at risk of having the mutated chromosome.

Why do mutations matter?



More than 1000 mutations have been identified in the gene linked to Fabry disease.



The type of mutation may help predict **when** symptoms appear, **what kind** of symptoms appear, and **how bad** the symptoms are or may become.



It's important to know which mutation you have.

If you want to learn about Fabry and its effects, contact your local patient organisation or talk to your healthcare professional.

Information in this guide came from the following sources.

DP Germain, Fabry disease, Orphanet J Rare Dis, 2010

PJ Meikle, JJ Hopwood, AE Clague, WF Carey, Prevalence of lysosomal storage disorders, JAMA, 1999

SM Rombach, N Dekker, MG Bouwman, and others, Plasma globotriaosylsphingosine: diagnostic value and relation to clinical manifestations of Fabry disease, Biochim Biophys Acta, 2010

RJ Desnic, R Brady, J Barranger, and others, Fabry disease, an under-recognized multisystemic disorder: expert recommendations for diagnosis, management, and enzyme replacement therapy, Ann Intern Med, 2003

BA Wehmann, Learning you have Fabry's disease: reactions and feelings, (www.fabry.org/FSIG. nsf/Pages/Online)

Z Yousef, PM Elliott, F Cecchi, and others, Left ventricular hypertrophy in Fabry disease: a practical approach to diagnosis, Eur Heart J, 2013

E Schäfer, K Baron, U Widmer, and others, Thirty-four novel mutations of the GLA gene in 121 patients with Fabry disease, Hum Mutat, 2005

A Gal, E Schäfer, I Rohard, The genetic basis of Fabry disease, Fabry Disease: Perspectives From 5 Years of FOS (A Mehta, M beck, G sunder-plassman), Oxford PharmaGenesis, 2006

G Cammarat, P Fatuzzo, MS Rodolico, and others, High variability of Fabry disease manifestations in an extended Italian family, Biomed Res Int, 2015

MH Branton, R Schiffmann, SG Sabnis, and others, Natural history of Fabry renal disease: influence of a galactosidase A activity and genetic mutations on clinical course, Medicine (Baltimore), 2002

© Amicus Therapeutics UK Ltd

1 Globeside Fieldhouse Lane Marlow Buckinghamshire SL7 1HZ

A company registered in England and Wales (registration number 05541527)

NP-NN-UK-00010722

Date of preparation: July 2022

